Literature DB >> 7987817

Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy.

S H Cho1, A Sahin, G N Hortobagyi, W N Hittelman, K Dhingra.   

Abstract

Sialyl-Tn (STn) antigen represents an aberrant glycosylation product of cell surface mucin in adenocarcinomas. We studied its expression in 40 breast carcinomas (35 of which included in situ carcinomas) by performing immunostaining with B72.3 monoclonal antibody. STn expression was observed in 50% of cases and was equally frequent in in situ and in invasive carcinomas. Positive STn staining significantly correlated with high nuclear grade (P = 0.001), aneuploidy (P < 0.001) and high S-phase fraction (P = 0.02). No correlation was observed between STn staining and age, menopausal status, presence of invasive component, or hormone receptor positivity. STn staining may provide an objective marker of dedifferentiation of breast tumors and should be investigated further for its prognostic value in breast cancers and as a biomarker of malignant transformation of breast epithelium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987817

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Sialyltransferases in cancer.

Authors:  F Dall'Olio; M Chiricolo
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

2.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

3.  Multiplex RT-PCR method for the analysis of the expression of human sialyltransferases: application to breast cancer cells.

Authors:  M A Recchi; A Harduin-Lepers; Y Boilly-Marer; A Verbert; P Delannoy
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

4.  Breast cancer cells expressing cancer-associated sialyl-Tn antigen have less capacity to develop osteolytic lesions in a mouse model of skeletal colonization.

Authors:  Ryo Fujita; Hiroki Hamano; Yusuke Kameda; Ryuta Arai; Tomohiro Shimizu; Masahiro Ota; Dai Sato; Hideyuki Kobayashi; Norimasa Iwasaki; Masahiko Takahata
Journal:  Clin Exp Metastasis       Date:  2019-10-08       Impact factor: 5.150

Review 5.  Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression.

Authors:  Ivan O Potapenko; Vilde D Haakensen; Torben Lüders; Aslaug Helland; Ida Bukholm; Therese Sørlie; Vessela N Kristensen; Ole C Lingjaerde; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2009-12-11       Impact factor: 6.603

6.  Clinicopathologic and Prognostic Significance of the Expression of Mucins, Simple Mucin Antigens and Histo-Blood Group Antigens in Papillary Thyroid Carcinoma.

Authors:  Pedro Alves; Paula Soares; Simone Rossi; Elsa Fonseca; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

7.  Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA.

Authors:  S Julien; M A Krzewinski-Recchi; A Harduin-Lepers; V Gouyer; G Huet; X Le Bourhis; P Delannoy
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

8.  A rat model to study the role of STn antigen in colon cancer.

Authors:  S Ogata; I Ho; J Maklansky; A Chen; J L Werther; M Reddish; B M Longenecker; E Sigurdson; S Iishi; J Y Zhang; S H Itzkowitz
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

9.  Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model.

Authors:  Hidenori Ozaki; Hideki Matsuzaki; Hidenobu Ando; Hiroyuki Kaji; Hayao Nakanishi; Yuzuru Ikehara; Hisashi Narimatsu
Journal:  Clin Exp Metastasis       Date:  2012-01-08       Impact factor: 5.150

10.  Sialyl-tn in cancer: (how) did we miss the target?

Authors:  Sylvain Julien; Paula A Videira; Philippe Delannoy
Journal:  Biomolecules       Date:  2012-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.